Quarterly report pursuant to Section 13 or 15(d)

CollabRx Acquisition (Details)

v2.4.0.6
CollabRx Acquisition (Details) (USD $)
 6 Months Ended
Sep. 30, 2012
Jul. 12, 2012
Business Acquisition [Line Items]    
Business acquisition effective date Jul. 12, 2012  
Acquisition agreement date Jun. 29, 2012  
Percentage of interests acquired (in hundredths)   100.00%
Number of shares issuable to acquire business (in shares) 236,433  
Shares issued specified as percentage of total shares outstanding (in hundredths) 14.00%  
Interest rate on promissory note (in hundredths) 0.28%  
RSUs and options granted as "inducement grants" to newly hired management (in shares) 368,417  
Vesting period of equity awards 4 years  
Noncompetition period 3 years  
Stockholders Agreement Period of transfer restrictions and voting provisions 2 years  
Assets acquired: [Abstract]    
Cash   $ 476,000
AP and Accrueds   (333,000)
Deferred Tax Liability   (664,000)
Goodwill   603,000
Total Acquired Assets, net   1,732,000
Purchase Price summary:    
Common Stock Consideration   932,000
Promissory Note Assumed 500,000 500,000
Loan/Note Payable Assumed   300,000
Total Purchase Price   1,732,000
Number of clinical and scientific advisors 50  
"Big data" opportunity value 300,000,000,000  
Developed Technology [Member]
    
Assets acquired: [Abstract]    
Intangible assets   720,000
Customer Relationships [Member]
    
Assets acquired: [Abstract]    
Intangible assets   433,000
Trade Name [Member]
    
Assets acquired: [Abstract]    
Intangible assets   346,000
Non Compete Agreements [Member]
    
Assets acquired: [Abstract]    
Intangible assets   $ 151,000